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Abstract
Background: During the 2009 influenza A/H1N1 pandemic, adjuvanted influenza vaccines were used for the first
time on a large scale. Results on the effectiveness of the vaccines in preventing 2009 influenza A/H1N1-related
hospitalisation are scanty and varying.
Methods: We conducted a matched case-control study in individuals with an indication for vaccination due to
underlying medical conditions and/or age ≥ 60 years in the Netherlands. Cases were patients hospitalised with
laboratory-confirmed 2009 A/H1N1 influenza infection between November 16, 2009 and January 15, 2010. Controls
were matched to cases on age, sex and type of underlying medical condition(s) and drawn from an extensive
general practitioner network. Conditional logistic regression was used to estimate the vaccine effectiveness (VE = 1
- OR). Different sensitivity analyses were used to assess confounding by severity of underlying medical condition(s)
and the effect of different assumptions for missing dates of vaccination.
Results: 149 cases and 28,238 matched controls were included. It was estimated that 22% of the cases and 28% of
the controls received vaccination more than 7 days before the date of onset of symptoms in cases. A significant
number of breakthrough infections were observed. The VE was estimated at 19% (95%CI -28-49). After restricting the
analysis to cases with controls suffering from severe underlying medical conditions, the VE was 49% (95%CI 16-69).
Conclusions: The number of breakthrough infections, resulting in modest VE estimates, suggests that the MF-59™
adjuvanted vaccine may have had only a limited impact on preventing 2009 influenza A/H1N1-related
hospitalisation in this setting. As the main aim of influenza vaccination programmes is to reduce severe influenza-
related morbidity and mortality from influenza in persons at high risk of complications, a more effective vaccine, or
additional preventive measures, are needed.
Background
Vaccination is the mainstay of preventing and mitigating
the impact of influenza in spite of moderate vaccine
effectiveness (VE). Lowering the burden of severe dis-
ease is one of the main aims of a vaccination program.
As influenza can be a precipitating factor for the exacer-
bation of underlying medical conditions, an influenza
vaccination strategy often targets specific risk groups.
Unfortunately, VE is generally lower in individuals with
a compromised immune system, such as the elderly [1].
Antigen supplies during a pandemic are expected to be
limited. For that reason, in 2005 the WHO recommended
adjuvanted vaccines in just such scenario [2]. Inclusion of
an adjuvant enhances immunogenicity of a vaccine [3],
thereby reducing the amount of antigen required for
equivalent immune responses. During the recent 2009
influenza A/H1N1 (pH1N1) pandemic, adjuvanted influ-
enza vaccines were used for the first time on a large scale
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in Europe. Five vaccines were authorised by the European
Medicines Agency (EMA) for use in the European Union
[4]. Clinical trials reported high immunogenicity of the
adjuvanted vaccines [5-10]; post-marketing studies
[11-16] showed an effectiveness on preventing confirmed
pH1N1 that was similar to that of seasonal influenza vac-
cines in well matched years [11,17]. So far, only limited
and varying results have been reported on the effective-
ness of the adjuvanted vaccines in preventing severe dis-
ease of pH1N1 that required hospitalisation [13,14,18].
VE estimates with severe outcomes are important for
guiding decisions on recommendations for complemen-
tary or alternative public health measures, and for com-
munication to and preparedness of health care and the
society. Studies estimating VE in specific risk groups are
important, especially where new vaccines are used, as
those groups are generally not included in clinical trials.
Until now, none of the published studies on the effec-
tiveness of the vaccines in preventing pH1N1-related
hospitalisation [13,14,18] focussed on a MF-59™-adju-
vanted vaccine. We investigated the effectiveness of a
MF-59™-adjuvanted vaccine [19] in preventing pH1N1-
related hospitalisation in individuals with an indication
for vaccination due to underlying medical conditions
and/or age ≥ 60 years in the Netherlands. Such a study
was enabled by the mandatory notification of pH1N1
cases requiring hospitalisation. We combined the notifi-
cation data with data of an extensive general practi-
tioner (GP) network in the Netherlands (Integrated
Primary Care Information (IPCI) database [20,21])
employing a matched case-control design.
Methods
Study design and setting
We conducted a matched case-control study. As hospita-
lisation for pH1N1 infection was notifiable, case-data
were obtained through the routine infectious diseases
surveillance system [22,23]. In the Netherlands, all
patients hospitalised for suspected for pH1N1 infection
were swabbed and tested. The instructions were to per-
form a nose and a throat swab combined in one transport
medium. Laboratory confirmation was done by real-time
PCR for influenza virus type A and type A(H1N1) [24].
Following laboratory confirmation, the attending physi-
cian and the laboratory had the legal requirement to con-
tact the Municipal Health Service, who notified the case
by entering the reported data into the national password-
secured web-based routine surveillance database.
Reported data included information on underlying medi-
cal conditions in broad categories (pulmonary disease,
cardiac disease, diabetes mellitus, chronic kidney failure,
cancer and immunocompromised condition) and self-
reported vaccination status for the seasonal and pan-
demic vaccines. Missing data were retrieved through the
hospital physicians; before discharge the hospital physi-
cian would ask the patient directly, while after discharge,
GPs were contacted in case the GP of the patient was
known. Control-data were available anonymously in the
IPCI database. Details about the database have been
reported elsewhere [20]. In short, the IPCI database is a
longitudinal GP research database and contains electro-
nic patient records of about 500 GPs from all over the
Netherlands. This includes prescription data and specia-
lists’ letters. Currently there are over 750,000 active
patients, representing approximately 5% of the Dutch
population. As in the Netherlands, nearly all people are
registered with a GP, the patient population is represen-
tative of the Dutch population regarding sex and age,
except for a slight under representation of the elderly
population that is under care of medical practitioners in
nursing homes.
The IPCI database complies with European Union
guidelines on the use of medical data for medical
research. The Scientific and Ethical Advisory Board of
the IPCI project approved the study. Informed consent
was not required.
Vaccination programme
In the Netherlands, different groups were eligible for a
pandemic influenza vaccination in 2009: those with spe-
cified underlying medical conditions (pulmonary disease,
cardiac disease, diabetes mellitus, chronic kidney failure,
cancer, immunocomprised condition), pregnant women
in their second and third trimester, institutionalised indi-
viduals, individuals aged ≥ 60 years, children aged 6
months to 4 years, health care workers with potential for
direct patient contact, family members and caretakers of
individuals with high risk for severe disease or death, and
household members of children younger than 6 months.
The MF-59™ adjuvanted vaccine [19] was provided to
individuals with underlying medical conditions and/or
aged ≥ 60 years through the GP. Vaccination started in
week 45 (November 2, 2009), though the majority of the
GPs (99% of our control sample) provided vaccination
from week 46 (November 9, 2009) onwards. All persons
were offered two doses, two weeks apart. The 2009
influenza epidemic in the Netherlands started in week
41, peaked in week 46 with 190 cases per 100,000 inha-
bitants and ended in week 50 [25].
Study population
Cases were patients who had been hospitalised because
of a laboratory confirmed pH1N1 infection. Only cases
with day of symptom-onset between November 16, 2009
and January 15, 2010 and with information on vaccina-
tion history were included (see Figure 1). Pregnant
women were not included in the analysis. The date of
symptom onset of cases was used as the index date.
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Patients from the IPCI database were eligible as con-
trols when they had at least 1 year of valid database his-
tory available, when they were eligible for vaccination by
the GP due to underlying medical conditions and/or
advanced age, and when they were registered with a GP
that had consistent and complete registration of vaccina-
tions (58% of all GPs; see Figure 1). Underlying medical
conditions were extracted from the IPCI database using
International Classification of Primary Care (ICPC) codes
as well as free text terms and were aggregated into cate-
gories to make the level of information of the cases and
controls similar. Information on vaccination status and
date of vaccination were extracted using algorithms
based on ICPC code and open text fields including
brands and batch-code. Consistent registration of vacci-
nations was defined as a coverage of the seasonal influ-
enza vaccination, 1st dose of pandemic influenza vaccine
and 2nd dose of pandemic vaccine of ≥ 50% in the GP
practice population aged ≥ 60 years. This cut off was
based on the national vaccination coverage estimate of
the population aged ≥ 60 years in 2009 (respectively 76%,
77% and 69% [26]). From the selected eligible population,
we sampled all possible controls matching a case on age
(+/- 12 months), sex, underlying medical conditions (all
conditions at aggregated level) and calendar date (i.e.
were alive and present in the database for at least 1 year
at the index date). One case did not have a matched con-
trol. Women with known confirmed pregnancy (ICPC
codes; n = 43) and individuals that had been hospitalised
with confirmed or suspected pH1N1 infection before the
index date (open text fields; n = 17) were excluded.
Exposure definition
A case and the matched controls were considered
exposed (vaccinated) if they had received at least one
pandemic influenza vaccination more than 7 days before
symptom onset of the case [11,12,14,16]. The analysis
was repeated for those who were vaccinated more than
14 days before symptom onset of the case. If the exact
date of vaccination was unavailable, we extrapolated the
time between vaccination date and symptom onset from
vaccinated cases with a known date of vaccination. We
assumed that the availability of the date of vaccination
was independent of the day of symptom onset (see
Figure 2). Therefore, we applied the percentage of unex-
posed cases among those with known vaccination date
to vaccinees with unknown vaccination date. Further-
more, we assumed that vaccination less than 7 or 14
days before symptom onset (i.e. to be unexposed) was
more likely in the beginning of November.
Data analysis
Vaccine effectiveness was computed as VE = 1 - OR [27],
with an exact 95% confidence interval (CI) around the
point estimate. We used conditional logistic regression to
calculate the odds ratio (OR). We used the VE estimate
using the assumption on the validity of the vaccination
based on the vaccinated cases with known date of vaccina-
tion (see exposure definition) as our primary analysis.
Additionally, we used imputed delays between symptom
onset and date of vaccination for those with unknown date
of vaccination. We used multiple imputation (n = 10) and
sampled from a uniform distribution with a lower bound
of a delay of zero days and an upper bound of a delay of
the sum of the number of days since the start of the study
and 7 days. This upper bound is based on the start of the
vaccination campaign relative to the start of this study. The
overall estimates and 95%CI were determined using the
method described by Rubin [28]. Furthermore, we consid-
ered all vaccinated cases with unknown vaccination date to
be unexposed to yield the maximum VE.
Although we matched for underlying medical condi-
tions, we were not able to match on the severity of
these underlying medical conditions, as no such infor-
mation was available for our cases. It could be argued
that individuals hospitalised with pH1N1 suffer from
more severe underlying medical conditions than com-
munity controls with underlying medical conditions.
Therefore, we performed a post hoc sensitivity analysis
in which controls were sampled from the pool of con-
trols who received five or more different active drug
compounds prescribed in the year prior (above median
number) and matched on the same criteria as described
before. The number of active drug compounds was
therefore considered as a proxy of disease severity.
Data analysis was performed in SAS 9.2 (SAS Institute
Inc. Cary, NC, USA).
Results
Sample characteristics
Of the 583 laboratory confirmed pH1N1 patients that
were hospitalised during the study period, 459 (79%)
Confirmed cases notified: 2182
In study period: 583
Complete data on vaccination 
history and eligibility criteria: 459
Eligible: 149; matched: 148
# of GP records in IPCI: 750,492
Eligible for vaccination: 213,271
Cases until January 15, 2010 Controls
# of matched controls: 28,238
# of matched controls with 
severe underlying illness:10,830 
# of eligible patients of reliably 
registering GPs: 124,108
Eligible and matched (control with 
severe underlying illness): 138
Figure 1 Flow diagram of cases and controls. Cases are derived
from the routine infectious diseases surveillance system, controls
originated from the IPCI GP database.
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had complete data on matching factors and history of
vaccination. Only 149 were eligible for inclusion, as the
majority of cases had no indication for pandemic influ-
enza vaccination because of age (< 6 months; 19%) and/
or absence of an underlying medical condition (74%).
The majority of the included cases fell ill in November
2009 (Figure 2), which coincided with the peak of the
Dutch influenza epidemic. The median age of the
included cases was 48 years (range 1-84), and 44% were
male. Only 2% (n = 3) of the included cases was pre-
viously healthy (aged ≥ 60 years; of which two were
assumed exposed); all others suffered from underlying
medical conditions. Seven included cases died from
pH1N1.
Forty-six percent (n = 68) of the cases reported to have
obtained at least one pandemic influenza vaccination
(Table 1). Among the vaccinated cases, exact date of vac-
cination was available for only 49% (n = 33). Vaccinees
with or without available date of vaccination did not dif-
fer statistically on age (respectively 43 and 46 years old),
sex (48% and 34% male) or the presence of underlying
medical conditions (0/33 and 2/35). Furthermore, vacci-
nees without available date of vaccination who were
assumed to be exposed did not differ from those who
were assumed to be unexposed on age (respectively 51
and 57 years old), or the presence of underlying medical
conditions (0/18 and 2/17). Respectively 48% and 33% of
the vaccinated cases with exact date of vaccination avail-
able had obtained their vaccination more than 7 or 14
days before symptom onset (Table 1). Based on the extra-
polation from available dates of vaccination, we assumed
that 22% of the cases had received vaccination more than
7 days before the index date (exposed at symptom onset)
and 15% more than 14 days before the index date. Of the
seven fatal cases, four had obtained pandemic vaccina-
tion. For only one, date of vaccination was known. For
this case, symptoms started five days after vaccination,
too soon to expect an immune response from the vac-
cine. Two fatal cases (29%) were assumed to have been
exposed. In controls, 46% had obtained at least one dose
of pandemic influenza vaccination at the index date, of
which 60% more than 7 days and 29% more than 14 days
before the index date (Table 1). This resulted in a valid
vaccination coverage of respectively 28% (7 days) and
13% (14 days) in controls. Because of the matching in
which each stratum contains a single case, no direct
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Figure 2 Epidemiological curve of included cases by exposure. Cases who were exposed (black), or assumed to be exposed (dark grey), and
those whose vaccination was assumed to have taken place within 7 days before symptom onset (assumed unexposed; light grey) or who were
unexposed (white) are presented by day of symptom onset. The assumption on exposure was based on cases with known date of vaccination. *
For 1 patient, day of symptom onset was unknown. For this patient we used 1 day before day of admission as day of symptom onset for this
epidemic curve.
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comparison of vaccination coverage between cases and
controls should be made.
Vaccine effectiveness
A considerable number of breakthrough infections was
observed (Figure 2). The estimated VE was 19% (95%CI:
-28-49; Table 2). The analysis with imputed data yielded
a VE of 24% (95%CI -113-73). The maximum VE (all
cases with unknown date of vaccination were assumed
unexposed) was estimated at 74% (95%CI: 53-86).
The analysis using > 14 days as cut off for exposure
revealed a VE of < 0% (upper 95%CI 30). In case data
were imputed, the VE was estimated at 26% (95%CI
-160-79; Table 2).
Sensitivity analysis restricted to controls with severe
underlying medical conditions
After restricting our analysis to controls who were pre-
scribed at least five different types of medications (proxy
for more severe underlying medical conditions), the
control population included 10830 individuals (38% of
original control sample; see Figure 1). The number of
different prescriptions in the restricted population of
controls ranged from 5 to 52, with a median of 7 pre-
scriptions. Thirty-one percent of this selection of con-
trols had obtained vaccination more than 7 days before
the index date (Table 1), which resulted in a restricted
VE of 49% (95%CI: 16-69; Table 2). Using imputed data,
a similar result was obtained (VE = 51% (95%CI -43-
83)). The maximum VE using the restricted control
population was estimated at 84% (95%CI: 69-92).
Discussion
This matched case-control study showed a considerable
number of breakthrough infections, resulting in modest
VE estimates. These results suggest that the MF-59™
adjuvanted vaccine may have had only a limited impact
in preventing pH1N1-related hospitalisation in risk
Table 1 Vaccination history and completeness of data in cases, controls and controls with severe medical conditions
Used cut off for
exposure
Cases Controls Controls with severe medical
conditions
Crude vaccination coverage 46% (68/149) 46% (13012/
28238)
53% (5752/10830)
Known vaccination date in vaccinees 49% (33/68) 100% (13012/
13012)
100% (5752/5752)
Exposed cases (known vaccination date) > 7 days
> 14 days
48% (16/33)
33% (11/33)
60% (7798/13012)
29% (3715/13012)
58% (3320/5752)
27% (1551/5752)
Assumed exposed cases (unknown
vaccination date)
> 7 days
> 14 days
49% (17/35)
31% (11/35)
NA
NA
NA
NA
(Assumed) vaccination coverage > 7 days
> 14 days
22% (16+17/
149)
15% (11+11/
149)
28% (7798/28238)
13% (3715/28238)
31% (3320/10830)
14% (1551/10830)
Data using different cut offs for the validity of vaccination are presented. Note that no direct comparison of vaccination coverage between cases and controls
should be made because of the matching in which each stratum contains a single case.
* NA = not applicable as for all controls, date of vaccination was available.
Table 2 Effectiveness of the pandemic influenza vaccine in preventing 2009 influenza A/H1N1-related hospitalisation
VE (%) (95%CI)
Exposed if > 7 days between vaccination and symptom
onset
Exposed if > 14 days between vaccination and symptom
onset
VE* 19 (-28-49) < 0 (upper 95%CI 30)
VE imputed data$ 24 (-113-73) 26 (-160-79)
Restricted VE 49 (16-69) 35 (-26-66)
Restr. VE
imputed$
51 (-43-83) 59 (-65-90)
Maximum VE# 74 (53-86) 61 (19-82)
The most realistic estimate of the vaccine effectiveness (VE), the VE estimation whereby we restricted our controls to those suffering from severe underlying
medical conditions (restricted VE) and the maximum VE are presented. Results derived using different cut offs to define exposure are presented using the
assumption based on cases with known date of vaccination and using imputed data.
* For 36 cases date of vaccination was missing. Respectively 49% and 31% of the vaccinated cases with unknown vaccination date were assumed to be exposed
using 7 days or 14 days as cut off for the validity of vaccination (extrapolation from cases with known date of vaccination).
$ We used multiple imputation and sampled (n = 10) from a uniform distribution with a lower bound of delay = 0 and an upper bound of delay = number of
days since the start of the study + 7 days. This upper bound is based on the start of the vaccination campaign relative to the start of this study.
# For the maximum VE, all vaccinees with unknown vaccination date were assumed unexposed.
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groups. Because pandemic vaccination started around
the peak of the pH1N1 epidemic in the Netherlands,
missing date of vaccination in hospitalised cases is a
severe limitation to this study. Applying different sce-
narios partly overcame this limitation and provided a
range of VE estimates, though, residual confounding by
time cannot be excluded.
As pandemics occur unexpectedly, and during pan-
demics available resources could be heavily stretched,
ideally routinely collected data should be used to provide
estimates of VE against severe outcomes. We showed
that using such data for VE estimates is feasible. How-
ever, observational studies to estimate the effectiveness of
influenza vaccination are prone to bias [29-33]. Our
study is not immune to such potential bias and although
we matched for potential confounding variables, we had
limited possibilities to adjust for residual confounding.
The use of different types of routinely collected health
care data and the consequent differences in the quality
and level of information between cases and matched con-
trols is a limitation of this study. In cases, vaccination sta-
tus was self-reported whilst in controls vaccination was
reported by the GP. GP registered data can be incomplete
because of unreliable registration and because vaccina-
tion was also offered outside GP practices for certain
individuals (e.g. those working in healthcare, those with
children under the age of 6 months, children under the
age of 5). By including controls who were eligible for vac-
cination by the GP and who were sampled from reliably-
registering GPs we aimed to minimise potential underes-
timation of the vaccination coverage in controls. Recall
bias in cases will have had only limited impact because of
the short delay between the vaccination campaign and
symptom onset, and because of the substantial attention
of the general population for the pandemic influenza
vaccine.
Frailty selection, resulting in confounding by severity,
can be important in VE studies focussing on severe dis-
ease or hospitalisation as outcome [30,31]. Because the
majority of the study population was relatively young
(median age 48 years), and suffered from one kind of
underlying medical condition, frailty is likely to have
been of lesser importance relative to studies on seasonal
influenza. Moreover, by matching our cases with controls
on underlying medical conditions, we decreased the
probability of confounding. However, because our cases
could have been suffering from more severe underlying
medical conditions than our matched controls, but with-
out preventing them to obtain the vaccine, we performed
a sensitivity analysis post hoc using controls with more
severe underlying conditions. Using this restriction, the
VE was estimated to be 35% (95%CI -26-66) or up to
59% (95%CI -65-90) depending on the cut off and
method used to define exposure. However, it is known
that several of our cases did not use any medication, sug-
gesting only mild underlying medical conditions in those
cases. These restricted VE estimates are therefore likely
an overestimation of the actual VE.
The estimates of the effectiveness in preventing
pH1N1-related hospitalisation of the adjuvanted pan-
demic influenza vaccines used in Europe ranged from
45% (95%CI 3-69; UK using a ASO3 adjuvanted vaccine
[14]) to 90% (95%CI 48-100; Spain using several vaccines
[18]) or even 100% (95%CI ∞-100; Scotland [13]). Even
our maximum VE estimate was not as high as the Span-
ish and Scottish estimates. To determine the maximum
VE, we assumed for all 35 cases with unknown date of
vaccination (51% of all vaccinees) that vaccination took
place within 7 days of symptom onset. This is unlikely a
realistic assumption and therefore the maximum VE esti-
mate is likely overestimated. A possible explanation for
the wide range of VE estimates in Europe is the differ-
ence in inclusion criteria, the control group and the used
vaccine. In Spain [18], the vaccine was mainly distributed
to the usual influenza risk groups (including those with
obesity), but all hospitalised patients were included in the
study. The UK study [14] and our Dutch study focussed
on the population most at risk for severe outcome of an
influenza infection, and therefore only included indivi-
duals eligible for vaccination because of an underlying
medical condition or advanced age. It is known that indi-
viduals with certain types of underlying medical condi-
tion or older age have a reduced response to vaccination
[34,35]. A lower VE is therefore expected in this suscepti-
ble population. Furthermore, earlier published studies on
VE against hospitalisation used the test-negative case-
control design [14,18]. This design is susceptible to
imperfect specificity and sensitivity of diagnoses and the
vaccine coverage in test-negative hospital cases is possi-
bly not representative for the general population. In addi-
tion, differential health care seeking behaviour between
test-positives and test-negatives could result in biased
estimates. As we used national data of notifications and
data of an extensive GP network which are representative
for the country, we expect that our cases and controls
originate from the same, general population. However,
our data have limited possibilities to refute the presence
of potential bias which may have led to an underestima-
tion of the VE.
The pandemic influenza vaccine used [19] contained
half the amount of antigen relative to seasonal influenza
vaccines plus an adjuvant to increase the immunogenicity.
It is therefore not possible to make a direct comparison to
seasonal influenza vaccines. However, the effectiveness of
seasonal influenza vaccines in preventing influenza-related
hospitalisations is also under debate. For seasonal influ-
enza vaccination, a low VE estimate against hospitalisation
(9-12%) was observed in those aged > 50 years using a
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difference-in-differences design [36]. Additionally, a
Cochrane review concluded that seasonal influenza vacci-
nation had no effect on hospital admissions or complica-
tion rates [17]. Taking into account the differences in
study design and vaccines used, the effectiveness of influ-
enza vaccines to prevent influenza-related hospitalisation
appears lower than the effectiveness in preventing clinical
disease [11-16]. The fact that those most at risk of compli-
cations and hospitalisations due to influenza react less
favourably to the vaccine may have contributed to this dif-
ference. Adding the adjuvant to the vaccine did not over-
come this problem in our population.
Conclusion
In conclusion, the number of breakthrough infections
resulting in a modest VE estimates suggests that the MF-
59™ adjuvanted vaccine may have had only a limited
impact on preventing pH1N1-related hospitalisation in
this setting. As the main aim of influenza vaccination
programmes is to reduce severe influenza-related mor-
bidity and mortality from influenza in individuals at high
risk of complications, a more effective vaccine, or addi-
tional preventive measures, are needed. Furthermore,
efforts should be made to put better real-time monitoring
systems in place to study the effectiveness of influenza
vaccines in preventing severe laboratory-confirmed
influenza.
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